Changing Landscape of Treatment of HR+ and HER2- Metastatic Breast Cancer with PI3K and CDK 4/6 Inhibitors

Program Description This webcast is intended to improve the care of patients with HR+ and HER2- metastatic breast cancer by accelerating the adoption of new guidelines and evidence-based practice change. ...

Program Description
This webcast is intended to improve the care of patients with HR+ and HER2- metastatic breast cancer by accelerating the adoption of new guidelines and evidence-based practice change. An in-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for the integration of novel therapeutic options.

Intended Audience
This webcast is designed to meet the educational needs of hematologists/oncologists and other health care professionals who diagnose, treat, and manage patients with HR+ and HER2- metastatic breast cancer.

Commercial Supporter
Supported by Novartis Pharmaceuticals Corporation

---

Write the first review

Resource tags